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Introduction
In the future, an increasing numbers of patients will be on antithrombotic treatment with novel oral anticoagulants, the first in clinical use being the direct oral thrombin inhibitor dabigatran (Pradaxa ® ) for patients with non-valvular atrial fibrillation. A small percentage of the patients on dabigatran will experience serious bleeding or be in need of urgent surgery. In those instances, the clinicians need guidance how to treat the patient in order to arrest or prevent bleeding. In contrast to warfarin, none of the non-vitamin K antagonist oral anticoagulants (NOAC) have a specific antidote approved yet. Nevertheless, in a recent analysis of 5 phase III clinical trials, patients who experienced major bleeding with dabigatran required more red blood cells but received less plasma, experienced a shorter stay in the intensive care unit and had a trend towards lower mortality (p=0.051) compared with those who had major bleeding with warfarin [1] . An antibody directed towards dabigatran developed by BoehringerIngelheim has shown very promising results in vitro and in a rat model [2] . A phase III study has started recruiting patients (NCT02104947) but approval for use in humans will take years.
Hemodialysis is effective in removing dabigatran, but the method is time-consuming and may lead to bleedings at insertion sites. In vitro studies, animal models and case reports on the use of recombinant factor VIIa (rVIIa), prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (APCC), reviewed by Majeed and Schulman recently [3] , have reported both promising and disappointing results. Due to the clinical need there are recommendations or proposals on the use of PCC, APCC or rFVIIa in severe bleeding if other measures are insufficient, despite scarce supporting evidence (see national Swedish recommendations http://ssth.se/documents/vp/vpeng120213.pdf and references [3] [4] [5] [6] [7] [8] [9] [10] ). The aim of our study was to 1) provide the medical community with data on in vitro effects by different hemostatic agents to support decision-making on reversal of 2) inspire further testing in animal models and clinical studies.
Whole blood was spiked with the active substance dabigatran at expected peak concentrations and the effects of drugs potentially improving coagulation were tested. We utilized a viscoelastometric clotting assay using the instrument ReoRox ™ and measured clot initiation and propagation velocity from a tissue factor covered surface using the instrument Thrombodynamics Analyzer ™ . The effects of PCC, APCC and rFVIIa were tested.
Materials and Methods

Blood samples and spiking with dabigatran
The analyses involved samples from up to twenty adult healthy volunteers (numbers in figure legends), both men and women were included. The blood samples were anonymized at time of blood collection. The procedure was approved by the local ethical committee, although no specific approval for this procedure of blood collection is required. Blood was collected in 
Reversal drugs tested
The chosen concentrations are based on typical clinical dosage for reversal of warfarin (PCC)
or treatment of hemophilia with inhibitors (rFVIIa, APCC). All drugs were reconstituted according to the recommendations of the manufacturer.
For recombinant activated factor VII (NovoSeven , Novo Nordisk, Bagsvaerd, Denmark), standard treatment of 90 µg/kg was chosen, and in some experiments the concentration was tripled corresponding to high-dose treatment. This represents final concentrations in blood of 2.1 µg/mL and 6.3 µg/mL, respectively.
Activated prothrombin complex concentrate, FEIBA ® (Baxter AG, Vienna, Austria), was used at a final concentration of 1.8 U/mL of blood.
Prothrombin complex concentrate (PCC), Cofact ® (Sanguin, Amsterdam, the Netherlands) was used. Based on the treatment regimen of 40 U/kg we added 0.56 U/mL blood, i.e. 22.4 μL per mL blood.
Measurements of visco-elastic parameters
Viscoelastometric measurements were performed on whole blood using free oscillation rheometry (FOR, determined by two four-channel ReoRox2 ™ instrument from Medirox AB, Nyköping, Sweden). We used disposable polypropylene sample cups and software The run time was set to 60 minutes.
Measurement of clot initiation and propagation from a tissue-factor coated surface
A method utilizing video-image capture and processing developed for the analysis of blood plasma coagulation at a tissue factor-coated surface, specially prepared with low density of tissue factor, was performed on the instrument Thrombodynamics Analyzer™ (HemaCore, Moscow, Russia). This method has been described in several articles [12] [13] [14] . Coagulation was detected in a cuvette by time-lapse image capture of light scattering from the fibrin network. By image processing and analysis, both the initiation (lag time in minutes, data not shown) and propagation phase (initial rate of clot growth; µm/min) of the coagulation process were measured in the same experiment. The experiments were done using PRP. The results were normalized due to differences between batches of reagents to enable presentation in one figure with the mean of controls for each batch of reagent set to 100%.
Statistics
Results are expressed as the mean values ± standard deviation (SD). Statistical significance was tested using the non-parametric Mann-Whitney test since the numbers may not be enough for proper testing of Gaussian distribution and is denoted as follows; *P<0.05, **P<0.01, and ***P<0.001.
Results
APCC shortened clotting time considerably in samples spiked with dabigatran ( Fig. 1) . In contrast, PCC had no effect on the prolongation caused by dabigatran (Fig. 1) , but prolonged clotting time in absence of dabigatran, although not significant using Mann-Whitney test.
rFVIIa shortened the clotting time in the sample spiked with dabigatran with 12%±28%
(mean change in percentage ±SD) but also shortened the clotting time in the control sample (not shown). Increasing the concentration of rVIIa three times induced further shortening of the clotting time to a reduction of 26%±32% (Fig. 2) , but the effect of tripling the concentration of rFVIIa was not significant. Dabigatran seemed to attenuate the initial rate of coagulation clot growth from 27 to 19 µm/min at the tissue factor-coated surface (although not significant using Mann-Whitney test). APCC increased the rate by 20%±31% in presence of dabigatran, a significant increase using Mann-Whitney test (Fig. 3) . In the presence of dabigatran, rFVIIa and PCC did not restore initial clot growth, PCC even slightly decreased the initial clot growth, although not significantly (Fig.3) .
Discussion
Dabigatran is a specific inhibitor for thrombin. Agents causing large increase of the good effects by APCC on thrombin generation parameters using the calibrated automated thrombography [15, 16] and on clotting analysis done on blood samples collected from healthy subjects infused with PCC and APCC [17] . Furthermore, the prolonged R-time in thromobelastography (which is related to clotting time) on blood samples from eight patients on dabigatran (150 mg twice daily) was shortened, although not normalized, by addition of rFVIIa but not by PCC in a recent study [18] . In addition the R-time was also prolonged in thromboelastography and ROTEM analysis in blood samples from patients on dabigatran, but effects of reversal drugs not tested in these instruments in the recent study by Herrmanns et al [16] .
There is still very limited evidence for efficacy of reversal of anticoagulant effect of dabigatran. PCC improved haemostasis in a rabbit kidney injury model [19] and prevented excess intracerebral haematoma expansion in a murine intracerebral hemorrhage model [20] .
PCC, APCC, rFVIIa all decreased the prolonged bleeding time in a rat tail bleeding model, but routine coagulation assays did not predict this effect. Thrombin generation reversal was dependent on the concentration of dabigatran and each reversal drug normalization occurred at the lower concentration of dabigatran with most agents, but not at higher concentrations [21] . In humans the results are less convincing. In published cases with life-threatening bleeding often more than two or more drugs potentially improving haemostasis have been used which makes it hard to evaluate the effect of each drug, as for example in reference [22] , or the treatment failed as in a case with total hip replacement [23] . The clinical effect after using rFVIIa at a dose of 30 µg/kg in one complicated case which presented with rectal bleeding was unsatisfactory [24] as well as in one fatal case treated with dabigatran as postoperative prophylaxis [23] . In contrast, in one case of severe bleeding due to a transseptal perforation at an atrial fibrillation ablation procedure bleeding was stopped by infusion of 26 U/kg APCC [25] . In a fatal case with dabigatran-associated intracranial hemorrhage, rFVIIa at 90 µg/kg body weight shortened the prolonged activated partial thromboplastin time and the prothrombin time, improved thrombin generation and shortened the R-time [26] . Case reports thus show conflicting results [23] [24] [25] [26] [27] . Furthermore, a very important limitation regarding case studies is that only a small fraction of cases are reported in the literature or available through other open sources.
Clinical guidelines suggest the use of PCC, APCC or rFVIIa in patients on dabigatran who suffer severe bleeding [1, [3] [4] [5] [6] [7] [8] [9] [10] . In our opinion, based on this study and the few case reports and in vitro and ex vivo studies, for a critically bleeding patient on dabigatran our choice would be rFVIIa in the highest dosage used in this study to get maximal effect or APCC in same dosage as for treatment of hemophilia patients with inhibitors.
In conclusion, APCC and rFVIIa seem to have the potential for reversal of dabigatran effects on coagulation, but may in too high doses induce excessive coagulation and eventually cause thrombotic complications. PCC had less of an effect in the concentration used in this study but we cannot exclude that a higher concentration would be more efficient. There is a need for a specific reversal drug not increasing the risk for thrombosis and a monoclonal antibody has shown promising results in vitro and in animal models [2] and is in a phase III clinical study.
Large registry studies and randomized clinical trials are needed to provide evidence of potential benefit and harm of the hemostatic drugs for reversal of dabigatran effects on haemostasis in patients with major or life-threatening bleeding.
FIGURES
Figure 1
Activated prothrombin complex concentrate (APCC) but not prothrombin complex concentrate (PCC) shortened clotting time in blood and blood spiked with dabigatran (200µg/L). Clotting was initiated with tissue factor (1.4 pmol/L), control and with dabigatran only, both n=16. The final concentrations of reversal drugs and n were APCC (1.8 U/mL, n=10) and PCC (0.56 U/mL, n=16), respectively. Using Mann-Whitney test * p<0.05, ** p< 0.01 and *** p<0.001.
Figure 2
Recombinant factor VIIa (rFVIIa) shortened clotting times in blood and in blood spiked with dabigatran (200µg/L). Clotting was initiated with tissue factor (1.4 pmol/L), control and with dabigatran only, both n=16. The final concentrations of the reversal drug and n were rFVIIa (2.1 µg/mL, n= 20 and 6.3 µg/mL, n=4). Using Mann-Whitney test *** p<0.001.
Figure 3
Initial clot growth normalized for each batch reagents with mean of controls set to 100%, n=16. Dabigatran (n=16) attenuated initial clot growth which was slightly decreased by prothrombin complex concentrate (PCC). Activated prothrombin complex concentrate (APCC) even increased initial rate of clot growth in blood with dabigatran (200 µg/L significantly using Mann-Whitney test. Recombinant factor VIIa had no significant effect on initial clot growth in the presence of dabigatran (200 µg/L). The final concentrations of reversal drugs and n were APCC (1.8 U/mL, n= 6) PCC (0.56 U/mL, n=6) and rFVIIa (2.94 µg/mL, n=12) Using Mann Whitney-test * p<0.05, ** p< 0.01 and *** p<0.001. The small difference between control and dabigatran was not significant.
